FDA approves first treatment for Pediatric MS

Webdog · May 18, 2018

https://www.nationalmssociety.org/About-the-Society/News/FDA-Expands-Use-of-Gilenya®-(fingolimod)-for-Child

(bolding in original)

National MS Society said:

“As the first therapy specifically approved to treat children and teens with MS, this is a major milestone,” said Kathy Costello, MS, ANP-BC, MSCN, Associate Vice President of Healthcare Access at the National MS Society.

“The Society has been working on this issue for more than a decade, creating awareness and consistency around the diagnosis and care of children with MS,” said Cyndi Zagieboylo, President and CEO of the National MS Society. “We are a global leader in this field and are pleased to see the Society’s early and fundamental work helped lay the groundwork for this important breakthrough.”
Click to expand...

National MS Society said:

The U.S. Food and Drug Administration has approved Gilenya® (fingolimod, Novartis AG) for use in the treatment of children and adolescents 10 years of age or older with relapsing MS, making it the first therapy approved for the treatment of pediatric multiple sclerosis.
Click to expand...

Log in or Sign up

FDA approves first treatment for Pediatric MS

Webdog Senior Member (Voting Rights)

Share This Page

Log in or Sign up

FDA approves first treatment for Pediatric MS

Webdog Senior Member (Voting Rights)

Share This Page

Useful Searches